Lower Drug Dose Spells Trouble For Pharmacogenetic Test
This article was originally published in The Gray Sheet
A study published in the June 20 issue of the Journal of Clinical Oncology shows that a genetic test is unnecessary in children if the cancer drug irinotecan is given in a low dose over a period of days
You may also be interested in...
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.